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Abstract
Background: Guillain-Barre´ syndrome (GBS) is a post-infectious polyradiculoneuropathy, frequently associated with
antecedent Campylobacter jejuni (C. jejuni) infection. The presence of sialic acid on C. jejuni lipo-oligosaccharide (LOS) is
considered a risk factor for development of GBS as it crucially determines the structural homology between LOS and
gangliosides, explaining the induction of cross-reactive neurotoxic antibodies. Sialylated C. jejuni are recognised by TLR4
and sialoadhesin; however, the functional implications of these interactions in vivo are unknown.
Methodology/Principal Findings: In this study we investigated the effects of bacterial sialylation on phagocytosis and
cytokine secretion by mouse myeloid cells in vitro and in vivo. Using fluorescently labelled GM1a/GD1a ganglioside-
mimicking C. jejuni strains and corresponding (Cst-II-mutant) control strains lacking sialic acid, we show that sialylated C.
jejuni was more efficiently phagocytosed in vitro by BM-MW, but not by BM-DC. In addition, LOS sialylation increased the
production of IL-10, IL-6 and IFN-b by both BM-MW and BM-DC. Subsequent in vivo experiments revealed that sialylation
augmented the deposition of fluorescent bacteria in splenic DC, but not macrophages. In addition, sialylation significantly
amplified the production of type I interferons, which was independent of pDC.
Conclusions/Significance: These results identify novel immune stimulatory effects of C. jejuni sialylation, which may be
important in inducing cross-reactive humoral responses that cause GBS.
Citation: Huizinga R, Easton AS, Donachie AM, Guthrie J, van Rijs W, et al. (2012) Sialylation of Campylobacter jejuni Lipo-Oligosaccharides: Impact on
Phagocytosis and Cytokine Production in Mice. PLoS ONE 7(3): e34416. doi:10.1371/journal.pone.0034416
Editor: Susan Kovats, Oklahoma Medical Research Foundation, United States of America
Received August 19, 2011; Accepted February 28, 2012; Published March 28, 2012
Copyright:  2012 Huizinga et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was financially supported by an EFIS-IL Fellowship (to RH) and a Pathological Society of Great Britain and Ireland pilot project grant (to ASE).
CSG is supported by an Arthritis Research UK Non-clinical Career Development Fellowship (No. 17653). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Carl.Goodyear@glasgow.ac.uk
. These authors contributed equally to this work.
Introduction
C. jejuni is one of the most common causes of bacterial
gastroenteritis affecting approximately 50 per 100,000 individuals
each year in Europe [1]. In most cases, gastroenteritis resolves
within a week, however, a minority of infected individuals develop
post-infectious GBS. This is a life-threatening neurological disease
in which peripheral nerves including spinal roots are damaged
(polyradiculoneuropathy), leading to a rapid and ascending
paralysis of the extremities. Patients with a preceding C. jejuni
infection have a more severe form of GBS with poorer outcome as
compared to patients without preceding C. jejuni infection [2].
Nerve damage that precipitates C. jejuni-related GBS is the result
of antibodies that are generated against sialylated LOS present on
C. jejuni [2]. These antibodies cross-react with structurally similar
glycolipids present on peripheral nerve membranes, and initiate
complement activation and neuronal degeneration [3,4]. Animal
studies have demonstrated that C. jejuni LOS induces ganglioside-
reactive antibodies that lead to subsequent GBS-like paralysis
[5,6].
C. jejuni strains isolated from GBS patients more frequently
express the enzyme Campylobacter sialic acid transferase-II (Cst-II),
which is responsible for the sialylation of LOS [7]. The sialic acid
residue is required for the structural homology between LOS and
gangliosides like GM1a and GD1a and crucially determines
antibody cross-reactivity [8]. Only a limited number of individuals
develop GBS after infection with C. jejuni and it is likely that
susceptibility is determined by both pathogen and host factors.
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Sialylation is known to be beneficial to many pathogens. In the
case of C. jejuni it increases epithelial invasiveness [9] and protects
against complement-mediated lysis [10]. In a possible example of
the ‘‘Red Queen effect’’, which symbolises the continuous
evolutionary battle between species, the mammalian immune
system has evolved sialic acid specific receptors, such as the rapidly
evolving Siglec family (sialic acid-binding immunoglobulin-like
lectins) [11]. While interaction of sialylated pathogens with Siglecs
typically results in reduced immune responses due to the presence
of ITIMs in many of the Siglecs, in the case of C. jejuni sialylation is
associated with increased host immune responses. For example, in
a cohort of patients with C. jejuni enteritis, sialylation was
associated with higher levels of specific IgM antibodies and an
increased severity of gastroenteritis, which may be the result of a
more robust immune response [12]. The specific role of sialylated
LOS in enhanced inflammatory responses was demonstrated
recently by in vitro studies showing that sialylated LOS more
efficiently stimulates human DC through TLR4, thus amplifying
DC-mediated B-cell proliferation [13]. Similarly, sialylated
pathogens may be more prone to scavenging by specialised
macrophages, as exemplified by binding of sialylated C. jejuni to
sialoadhesin, also known as Siglec-1 [14].
In the far majority of GBS patients, loss of self-tolerance is
transient. The mechanisms that drive this loss of tolerance and
subsequent re-establishment of tolerance are poorly understood.
Likewise, the precise mechanism by which sialylation affects the
immunogenicity of C. jejuni in vivo remains unknown. Given the
above evidence, it is likely that sialylation does not only supply the
requisite molecular mimicry to break tolerance, but also directly
drives more robust inflammatory responses which, in susceptible
individuals, may allow autoreactive B cell clones to bypass the
tolerance mechanisms.
We hypothesize that the selective binding of sialylated C. jejuni to
innate receptors like Siglecs and TLR4 results in targeting to
myeloid cell populations with high expression of these receptors
such as splenic metallophilic macrophages. These initial events
may alter signalling and crucially determine subsequent immune
responses by influencing processes like antigen presentation [15],
regulatory T cell expansion [16] and B-cell activation [17].
In this study we investigated the functional role of LOS
sialylation on cytokine responses and phagocytosis of C. jejuni by
murine myeloid lineage antigen presenting cells, macrophages and
DC. We show that the presence of sialic acids on C. jejuni promotes
enhanced phagocytosis in vitro by BM-MW but not BM-DC.
Furthermore, sialic acid on C. jejuni LOS results in increased
cytokine responses by both myeloid cell populations. The
increased phagocytosis by BM-MW did not translate into a
preferential uptake of sialylated C. jejuni by specialised macrophage
populations in the spleen in vivo. However a small increase was
noted in the number of splenic DC that ingested sialylated
bacteria. These DC may account for the selective and robust
increase in type I interferon production in response to sialylated C.
jejuni.
Results
BM-MW, but not BM-DC, show increased phagocytosis of
sialylated C. jejuni
To investigate the impact of C. jejuni sialylation on functional
responses by myeloid cells, we used different isogenic C. jejuni
strains. The GB2 and GB11 wildtype strains express LOS that
mimic gangliosides GM1a and GD1a, whereas the GB2 and
GB11 Cst-II mutant strains do not mimic gangliosides. All strains
were fluorescently labelled using CFSE in order to facilitate
tracking during phagocytosis. To ensure comparable fluorescence
intensities for the quantitative phagocytosis studies, we performed
flow cytometry after the CFSE-labelling. Figure S1 shows that the
mean fluorescence intensities of wildtype and Cst-II mutant strains
were indeed comparable (MFI 57.1 vs. 57.6 for GB2 wt and
mutant respectively, and MFI 83.7 vs. 81.2 for GB11 wt and
mutant respectively). The C. jejuni were heat-inactivated to prevent
dilution through bacterial cell division.
As sialylation has previously been shown to enhance the rate of
phagocytosis of Neisseria meningitides [18], we hypothesised that
sialylation of C. jejuni would result in increased phagocytosis by
myeloid cells. Labelled GB11 bacteria were added to BM-MW or
BM-DC and the fluorescence intensity was determined as a
measure of bacterial phagocytosis.
BM-MW incubated with sialylated GB11 wt showed higher
fluorescence intensities than BM-MW incubated with Cst-II
mutant GB11 (Figure 1A and B). The difference was most
pronounced after 30 min of incubation; the fold increase of cells
incubated with GB11 wt was 2.360.2 compared to 1.860.1 when
cells were incubated with GB11 Cst-II mutant bacteria (p,0.05; t
test). The intracellular location of the wildtype and knockout
bacteria was confirmed by microscopy (Figure S2). In contrast,
BM-DC showed no difference in fluorescence intensity between
cells incubated with GB11 wt and GB11 Cst-II mutant bacteria
(Figure 1C and D).
Although it remains to be determined, it is possible that the
sialylated epitope phagocytic receptor is a Siglec. Interestingly,
sialoadhesin, which binds to a2,3-linked sialic acids [13], could
facilitate the enhanced phagocytosis identified in BM-MW. In
support of this concept, Facs analysis demonstrated high
expression of sialoadhesin on BM-MW but not BM-DC. In
addition, sialoadhesin was upregulated on BM-MW but not on
BM-DC, following stimulation with C. jejuni LOS (Figure S3).
LOS sialylation enhances myeloid cell cytokine
production
Given the interaction of LOS with TLR4 and the potential
interaction of sialylated epitopes with Siglecs we investigated the
influence of C. jejuni sialylation on cytokine responses in myeloid-
derived antigen presenting cells. As other TLR/NLR ligands
present in C. jejuni may have confounding effects, we stimulated
BM-MW and BM-DC with a titrating dose of purified LOS
derived from GB11 wt and GB11 Cst-II mutant strains and
measured cytokine responses in the culture supernatant.
Overnight stimulation with C. jejuni LOS induced a strong dose-
dependent IL-6 and IL-10 response in BM-DC and BM-MW.
However, myeloid cells stimulated with GB11 wt LOS produced
significantly higher levels of IL-10 and IL-6 than cells stimulated
with Cst-II mutant GB11 derived LOS (p,0.05; paired t test;
Figure 2). This difference was observed using different concentra-
tions of LOS, starting as low as 1 ng/ml. Similarly, the production
of IFN-b, which is induced by C. jejuni following MyD88-
independent TLR4 activation [19], was significantly higher in
both BM-DC and BM-MW after 4 h stimulation with sialylated
LOS (Figure 2E and F). The importance of sialylation was further
studied using LOS derived from the additional sialylated and non-
sialylated isogenic C. jejuni strains GB2 wt and ko. BM-DC and
BM-MW stimulated with sialylated GB2 produced significantly
higher levels of IL-6 and IL-10, like GB11 wt, when compared to
the non-sialylated counterpart (data not shown). These results
confirm that the increased cytokine responsiveness is dependent on
the presence of a sialylated epitope.
To confirm that LOS induced BM-DC IL-10 production was
TLR4 dependent and that contamination was not present. BM-
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DC derived from the C3H/HeJ mouse strain (Tlr4 mutant, LPS
hyporesponsive) and the control C3H/HeN strain (LPS respon-
sive) were stimulated as before and IL-10 assayed. No IL-10 was
produced in the absence of TLR4 signalling (data not shown).
Thus confirming that following LOS stimulation, the sialylated
epitope enhanced IL-10 production is TLR4-dependent and that
contamination by other TLR/NLR ligands is highly unlikely in
our preparations.
C. jejuni is scavenged by macrophages in the splenic
marginal zone
Having demonstrated sialylation specific differences in macro-
phage phagocytosis in vitro, we subsequently investigated whether
in vivo phagocytosis of C. jejuni was also affected by sialylation.
Because sialylation also increases invasion and translocation over
gut epithelial tissues, potentially leading to unequal numbers of
bacteria in the blood stream, we injected CFSE-labelled GB2 wt or
Cst-II mutant bacteria intravenously into C57BL/6 mice and
isolated the spleens after various time points to assess C. jejuni
localisation.
CFSE-labelled GB2 was predominantly localised at the splenic
marginal zone. This could be demonstrated by CFSE positive
bacteria around the B-cell follicles at the border of the red and
white pulp. Fluorescent bacteria could be identified in the spleens
of animals sacrificed 15 min, 1 h or 3 h after i.v. injection.
However, after 6 h, very few fluorescent particles could be
observed. For (quantitative) colocalisation studies we therefore
used the 1 h and 3 h time points. Immunofluorescent staining for
sialoadhesin, which identifies marginal zone metallophilic macro-
phages, showed that both CFSE-labelled GB2 wt and Cst-II
mutant were present in the sialoadhesin-expressing macrophages
(Figure 3A and B). In the marginal zone, fluorescent bacteria were
also observed in cells that were negative for sialoadhesin
(Figure 4B, inset), suggesting uptake by marginal zone macro-
phages. Indeed, staining for CD209b (SIGNR1) on marginal zone
macrophages, showed that GB2 was also scavenged by this cell
type (Figure 3C and D).
The mean CFSE-positive area of digital images taken from the
spleens of injected animals was used as an indication of the amount
of bacteria present in each section. The percentage of the CFSE-
positive area within metallophilic macrophages or marginal zone
macrophages was used as a measurement of the co-localisation of
the C. jejuni within these macrophage populations.
There was no difference in the CFSE-positive area between
GB2 wt and Cst-II mutant-injected animals at either 1 h or 3 h
indicating that the same quantity of sialylated and non-sialylated
bacteria was deposited in the spleen following injection (Figure 4A).
When the percentage of CFSE-positive area within the sialoadhe-
sin or CD209b positive area was determined, no significant
differences were observed between GB2 wt and Cst-II mutant-
injected animals (Figure 4B and C).
To substantiate these findings to other phagocyte populations in
the spleen, Facs-analysis was performed using markers specific for
red pulp macrophages (F4/80), marginal zone metallophilic
macrophages (MOMA1), DC (CD11c) and neutrophils (Ly-6G/
C). The percentage of CFSE-positive splenocytes in GB2 wt
injected animals (1.0860.50%) was comparable to GB2 Cst-II
mutant injected mice (1.0160.20%). CFSE-labelled C. jejuni
Figure 1. Increased phagocytosis of sialylated C. jejuni by BM-MW. (A) BM-MW or (C) BM-DC were incubated with CFSE-labelled wt or Cst-II
mutant GB11 for 60 min at 37uC (open histograms) or 4uC (filled histograms). Phagocytosis of C. jejuni by F4/80+ cells or CD11c+ cells was quantified
as fold increase in fluorescence intensity using background fluorescence of 4uC, NaN3 cultured cells as a reference. Phagocytosis of sialylated wt GB11
and unsialylated GB11 for 0, 15, 30 and 60 min shows that sialylation increases C. jejuni phagocytosis by BM-MW (B) but not DM-DC (D). One
representative experiment out of 3 is shown (B and D; means 6 sd of triplicates). * p,0.05; t-test.
doi:10.1371/journal.pone.0034416.g001
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bacteria were detected in all phagocyte populations examined. No
differences were observed in the number of CFSE-positive
macrophages and neutrophils when comparing GB2 wt and Cst-
II mutant-injected animals. However, a modest though significant
increase was found in the number of DC that ingested the
sialylated bacteria (p,0.05; Figure 4D).
Figure 2. Sialylated GB11 LOS induces higher cytokine levels by myeloid cells. BM-MW (A, C and E) and BM-DC (B, D and F) were incubated
overnight (for IL-6 and IL-10) or for 4 h (IFN-b) with purified LOS derived from GB11 C. jejuni or Cst-II mutant C. jejuni and cytokine production was
measured by ELISA. Sialylated LOS induces more IL-10 (A and B), IL-6 (C and D) and IFN-b (E and F) than non-sialylated LOS. Graphs represent pooled
data as mean 6 standard error from 3 (IL-10 and IFN-b) or 4 (IL-6) independent experiments. * p,0.05; paired t-test, n.d.: not detectable.
doi:10.1371/journal.pone.0034416.g002
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Sialylation of C. jejuni results in increased type I interferon
production
We previously identified sialylation dependent differences in
cytokine responses by myeloid cells to C. jejuni LOS in vitro. To
determine if these effects were apparent after in vivo C. jejuni
stimulation, RNA was isolated from the spleens of C. jejuni treated
mice and the relative expression of a panel of cytokines was
determined by real-time quantitative PCR.
With the exception of IFN-c, all cytokines were expressed to a
higher level at 1 h than at 3 h (data not shown). Highly
upregulated cytokines, i.e. more than 25-fold compared to PBS-
injected animals, included IFN-a2, IFN-a4, IFN-b and IL-6
(Figure 5). Both IFN-a4 and IFN-b expression were significantly
higher in GB2 wt injected animals (fold increase of 214461410
and 5646183 respectively) compared to GB2 Cst-II mutant-
injected animals (fold increase of 2916260 and 64636; p,0.05;
Mann-Whitney U test). IFN-a2 was also expressed to a higher
level in GB2 wt-injected mice (fold increase of 5086309) as
compared to mutant-injected mice (fold increase of 1376102),
however this difference did not reach significance (p= 0.11; Mann-
Whitney U test). The expression of other cytokines, amongst
others TNF-a, IL-6, IL-10 and IL-1b, were not different between
GB2 wt and GB2 mutant-injected animals.
The production of high levels of IFN-a2 and IFN-a4 after
injection with C. jejuni may suggest involvement of pDC. To
investigate whether pDC contributed to the production of
cytokines especially type I IFN, we depleted pDC using the
mAb 120G8 [20] prior to i.v. injection of C. jejuni. Administration
of the depleting antibody significantly reduced the number of
PDC1+ B220+ cells in the CD11c+ CD11b2 population,
demonstrating that the large majority of splenic pDC were
depleted (Figure S4A). Induction of type I IFN as well as several
other cytokines (i.e., IL-6 and TNF-a) was observed in spleens of
pDC-depleted animals after injection with GB2 wt (Figure S4B).
There was no difference between pDC-depleted animals and
isotype control treated animals, indicating that the production of
cytokines, including type I IFN was pDC-independent.
To study whether the increased expression of type I IFN could
also be detected systemically, we measured cytokines in serum
samples collected either at 3 h or at 16 h after C. jejuni injection.
No IFN-a or IFN-b could be detected in serum samples of mice
injected with wildtype of Cst-II mutant C. jejuni strains.
In summary, although injection of both sialylated and
unsialylated C. jejuni induced the production of several pro-
Figure 3. Both sialylated and non-sialylated C. jejuni are scavenged by macrophages in the splenic marginal zone. Mice were injected
with CFSE-labelled GB2 wt (A and C) or Cst-II mutant (B) bacteria and spleens were isolated after 1 h. Spleen sections were stained for sialoadhesin (A
and B) or CD209b (C and D) and counterstained for B220 (purple). Insets show colocalisation of GB2 wt and ko bacteria with sialoadhesin and CD209b
positive macrophages.
doi:10.1371/journal.pone.0034416.g003
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Figure 4. Sialylation of C. jejuni increases in vivo phagocytosis by splenic DC but not macrophages. Mice were sacrificed 1 h or 3 h after
i.v. injection of PBS or CFSE-labelled GB2 (wt or Cst-II mutant). Bacterial deposition in spleen sections, stained for sialoadhesin, CD209b and B220, was
quantified as detailed in the Materials and Methods section. The CFSE-positive area of digital images was similar between GB2 wt and Cst-II mutant
injected animals (A). No differences were observed in the CFSE-positive area within MOMA1 (B) or CD209b-positive cells (C). For each mouse, 6
pictures from 2 spleen sections were used for analysis (n = 4). Using Facs-analysis, the number of CFSE-positive metallophilic macrophages
(Sialoadhesin+), red pulp macrophages (F4/80+), DC (CD11c+) and neutrophils (Ly-6G/C+) was determined per spleen (n = 3; D). Shown are means 6
sd. * p,0.05; t-test with Welch’s corrections.
doi:10.1371/journal.pone.0034416.g004
Figure 5. Increased type I interferon production in the spleens of GB2 wildtype injected animals. Mice were injected with PBS, GB2
wildtype or Cst-II mutant bacteria and spleens were isolated after 1 h. Spleen sections were homogenised for RNA extraction and cytokine expression
was analysed by real-time PCR. Data is expressed as fold increase (mean 6 sd; n = 4) compared to PBS-injected control animals. * p,0.05, Mann-
Whitney U test.
doi:10.1371/journal.pone.0034416.g005
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inflammatory cytokines in the spleen, sialylated C. jejuni was
significantly more effective in inducing a type I IFN response.
Discussion
LOS sialylation is a crucial factor in the pathogenesis of GBS as
the sialic acid residue is a major determinant of the structural
similarity with human nerve gangliosides. In addition, sialylation is
associated with more severe gastroenteritis and higher levels of C.
jejuni-specific IgM [12] indicating a stimulatory effect on host
immune responses. As myeloid cells drive innate and adaptive
immune responses, we hypothesised that sialylation of LOS affects
functional responses of myeloid cells, through interaction with
sialic acid specific receptors. Using a combination of in vitro and in
vivo models, we sought to investigate if sialylation influences the
responses of these cells in both their capacity to phagocytose C.
jejuni and their cytokine responses to purified LOS. Our results
show that sialylation of C. jejuni increases phagocytosis by BM-MW
in vitro, an effect most likely mediated by sialoadhesin, whereas in
vivo studies indicated a preferential uptake of sialylated C. jejuni by
splenic DC. The production of cytokines by myeloid cells was
clearly increased by sialylated C. jejuni. This effect was not only
observed in vitro by both macrophages and DC, but also in vivo,
where type I interferons were identified as major discriminators
between sialylated C. jejuni strains and their unsialylated counter-
part. The findings in this study will be crucial for further
understanding of the increased pathogenicity of sialylated C. jejuni
strains and its mechanisms to induce cross-reactive humoral
responses leading to GBS.
The functional implications of C. jejuni sialylation on myeloid
cells are not fully known. Following up on the recent findings by
Bax et al. [21] demonstrating that sialylation of C. jejuni LOS
modulates Th1/Th2 skewing by human DC, we further elucidate
the role of microbial sialylation on myeloid cell responses. While
sialylation of C. jejuni increased phagocytosis by cultured BM-MW
it did not increase phagocytosis by BM-DC. Sialoadhesin is
expressed on BM-MW but not BM-DC, suggesting that in vitro
sialoadhesin might mediate increased phagocytosis. In support of
this, a sialoadhesin-mediated phenomenon has previously been
reported with meningococci [18]. However, although the
increased phagocytosis of sialylated C. jejuni in vitro is likely
mediated by sialoadhesin, we did not find that C. jejuni was
preferentially taken up by sialoadhesin-positive marginal zone
metallophilic macrophages in the spleen. This discrepancy may be
explained by the absence of serum factors like complement and
immunoglobulin during the in vitro studies. Receptors recognising
complement are highly expressed by macrophage populations in
the marginal zone, explaining the preferential location of both
strains of C. jejuni. It must also be noted that in order to facilitate
tracking of C. jejuni, we made use of heat-inactivated bacteria,
which may differ substantially from live bacteria. For example, live
bacteria are able to change the composition of their outer core
depending on growth rate and environmental factors i.e.
temperature and availability of nutrients. In addition, the i.v.
injection of mice with heat-killed C. jejuni does not fully represent
the natural route of infection via the intestinal mucosa.
Nevertheless, our data are relevant for understanding the
pathogenesis of C. jejuni. As a consequence of bacterial transloca-
tion across epithelial barriers, bacteria may enter the blood stream
relatively early during disease. In mice infected i.g. with C. jejuni,
bacteraemia is present as early as 10 min after inoculation and
resolves within 24 h [22,23]. Transient bacteraemia is also thought
to occur in humans, especially in patients with high fever [24].
Skirrow et al. [25] reported that C. jejuni bacteraemia occurred in
0.3–5.9 per 1000 intestinal infections. The incidence increased
with age and was twice as frequent in men as in women. Most
probably the frequency of bacteraemia is underestimated, as it
occurs early in disease when blood cultures are rarely taken [24].
The crucial role of the spleen in the recovery from C. jejuni
bacteraemia is exemplified by a case report describing fatal
outcome after C. jejuni infection in a splenectomised patient [26].
Further studies to investigate the role of myeloid cells in immunity
to sialylated C. jejuni should take these bacterial changes into
account.
In agreement with our previous observations on LOS potency
in human DC [13], we demonstrated that sialylation of C. jejuni
LOS dramatically enhanced the in vitro production of cytokines,
both by macrophages and DC. We also found that both C. jejuni
strains induced a robust cytokine response in vivo, including type I
IFN, IL-10, IL-6, TNF-a and IL-12, in the spleen 1 h after
injection. Strikingly, the only difference between the strains was
found in the production of type I interferon which was higher in
mice injected with sialylated C. jejuni. This effect is most likely
attributed to increased signalling of sialylated LOS via TLR4 [13].
Our finding that more CD11+ DC, which are known to express
TLR4, were phagocytosing GB2 wt may explain the type I IFN
signature in response to sialylated bacteria. TLR4 activation leads
to both MyD88-dependent and MyD88-independent signal
transduction, the latter being responsible for the induction of
IFN-b [22]. In another study, C. jejuni has indeed been shown to
induce IFN-b in mouse BM-DC in a TLR-4 and TIR-domain-
containing adapter-inducing interferon-b (TRIF)-dependent man-
ner [19].
TLR2 in conjunction with TLR1 and TLR6 may also play a
role in the production of cytokines in response to C. jejuni [27]. Our
observation that IL-10, IL-6, TNF-a and other cytokines were not
significantly different between sialylated and non-sialylated strains
may be explained by the additional signalling of C. jejuni via TLR2,
thus decreasing the relative contribution of TLR4 signalling for
the production of these cytokines. Alternatively, our inability to
show a difference in IL-6 and IL-10 levels may represent the lack
of specificity in our assay, which looks at whole spleen tissue. This
does not take into account the microenvironment around
individual antigen presenting cells, such as DC, in which
differences in IL-6 and IL-10, consistent with our in vitro results,
may exist and influence nearby immune effector cells.
The increased induction of IFN-a and IFN-b by sialylated C.
jejuni may play a role in the subsequent production of anti-
ganglioside antibodies that cause GBS. Type I interferons directly
act on B cells by decreasing the threshold of BCR activation [28],
promoting isotype switching and increasing immunoglobulin
production [17]. Its crucial role in the immune response is further
illustrated by the fact that the antibody-augmenting effect of
complete Freund’s adjuvant can be largely attributed to the
production of type I IFN [29]. Because of its important role in
humoral immune responses, we speculate that the increased levels
of specific IgM responses in patients infected with sialylated C.
jejuni [12] may be due to the selective increase in type I IFN by the
sialylated pathogen. In susceptible persons, this increase could
subsequently facilitate the activation of ganglioside cross-reactive B
cells. In the study of Mortensen et al, no difference in IgG levels
was observed between subjects infected with sialylated and
unsialylated C. jejuni. It is possible that due to local production
type I IFN only affects newly activated B cells and has little
influence on long-lived plasma cells, which contribute the most to
peripheral IgG levels.
Importantly, treatment of hepatitis or multiple sclerosis patients
with IFN-a or IFN-b respectively can lead to the development of
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autoimmune neuropathies [30,31]. Although a systematic epide-
miologic study on this matter is lacking, it appears that type I IFN-
induced neuropathy is not a general effect but rather occurs in a
small minority of cases. Not only is it necessary that the B cells with
ganglioside cross-reactivity are present in the subject, the B cells
also need to be activated through the BCR, as type I IFN only
promotes humoral responses in a BCR-dependent manner [28].
This requires an infection with pathogens expressing ganglioside
mimics, such as C. jejuni or Haemophilus influenzae [32].
In conclusion, our data indicate that sialylation of C. jejuni results
in increased phagocytosis by murine macrophage in vitro and
increased scavenging of C. jejuni by splenic DC in vivo. Sialylated C.
jejuni is more effective at inducing cytokine responses by myeloid
cells, particularly type I interferons. Future studies must address to
what extent these cytokine responses contribute to exacerbated
disease and development of post-infectious complications such as
GBS by sialylated C. jejuni strains.
Materials and Methods
Culture and fluorescent labelling of C. jejuni
C. jejuni strains GB2 and GB11 were isolated from patients with
GBS, and the corresponding Cst-II mutant strains, producing
LOS lacking sialic acid were described previously [33]. Bacteria
were cultured on blood agar plates incubated at 37uC under
microaerophilic conditions and harvested after 48–72 h. To
obtain fluorescently labelled bacteria, cells were washed with
PBS and resuspended to an OD600 of 1.0. An equal volume of
2 mM CFDA-SE in PBS was added and cells were incubated for
30 min at 37uC and subsequently heat-inactivated for 1 h at 65uC.
Bacteria were washed twice with PBS and stored at 280uC in
PBS/10% glycerol until use.
Phagocytosis of C. jejuni by BM-MW and BM-DC
For BM-MW, C57BL/6 bone marrow cells (0.56106/ml) were
cultured in 90 mm Petri dishes (Sterlin, UK) in RPMI supple-
mented with 20% L-929 supernatant (containing M-CSF) and
incubated at 37uC in 5% CO2. Fresh medium was added on day
4. Adherent cells were harvested on day 7 using a cell scraper and
ice cold PBS. Purity was assessed by flow cytometry and was
typically .90% F4/80+. BM-DC were grown using a similar
protocol only the RPMI was supplemented with 10% X-63
supernatant (containing GM-CSF) with 10 ml of fresh RPMI/
10% X-63 added on day 4. Non-adherent cells were harvested on
day 8. Purity was assessed by flow cytometry and was typically
.70% CD11c+. For the phagocytosis assays, RPMI medium
supplemented with Ultra-low IgG foetal bovine serum (Invitrogen,
UK) was used to exclude the possibility of bovine IgG affecting
phagocytosis. Macrophages or DC (16106/ml) were incubated at
37uC with CFSE-labelled GB11 wt or mutant bacteria at a ratio of
10 or 20:1. As a control, cells were incubated in the presence of
5 mM NaN3 at 4uC. After 0, 15, 30 or 60 minutes, cells were
washed with ice cold PBS with 5 mM NaN3, stained with anti-
mouse F4/80 biotin or anti-mouse CD11c biotin and streptavidin
APC and measured on a Facs Calibur. For analysis, F4/80+ or
CD11c+ cells were gated and the mean fluorescence intensity
(MFI) of these cells (representing phagocytosed bacteria) was
determined and divided by the MFI of the 4uC, NaN3 cultured
controls for each time point (n = 3). The residual sample following
Facs analysis was centrifuged onto plates and visualised using an
Apotome microscope to confirm the intracellular location of the
bacteria.
Stimulation of myeloid cells by C. jejuni LOS
LOS was purified from C. jejuni using previously published
protocols [13]. BM-DC and BM-MW were generated as above and
cultured at 16105 cells per well in 96 well flat-bottom plates
(Nunc) with the appropriate concentration of LOS. The
supernatants were harvested after overnight culture at 37uC with
5% CO2 and analysed using an IL-6 ELISA kit from R&D and an
OptEIA IL-10 ELISA kit (BD Biosciences, UK). Supernatants
isolated after 4 h stimulation were used to determine IFN-b
production using ELISA (PBL InterferonSource, Piscataway, NJ).
For C3H/HeJ and C3H/HeN experiments, mice were purchased
from Harlan UK and BM-DC were generated as above.
Intravenous challenge of mice with C. jejuni
C57BL/6 mice (8–12 weeks old) were bred and housed under
standard laboratory conditions at the University of Glasgow
(Glasgow, Scotland). All experiments were performed under the
UK Home Office License.
A 200-ml suspension containing 108 bacteria (OD600 of 0.6), or
PBS as a negative control, was injected into the tail vein. Mice
were sacrificed after 15 min, 1 h or 3 h using CO2. Organs were
snap-frozen in OCT using liquid nitrogen. Alternatively, the
spleen was immediately passed through a 100-mm cell strainer and
splenocytes were kept on ice in PBS/2 mM EDTA for Facs-
analysis. pDC depletion was accomplished by administrating
250 mg 120G8 or isotype control antibody/mouse i.p. 24 h and
48 h before injection of bacteria.
Facs-analysis
Splenocytes were fixed with 2% paraformaldehyde in PBS on
ice for 30 min, washed and incubated with 5 mg/ml Fc-block (BD)
for 30 min. Primary antibodies were added to the cells (66105
cells/staining): biotinylated anti-F4/80 (10 mg/ml; clone BM8;
Biolegend), biotinylated anti-CD11c (10 mg/ml; clone HL3; BD),
biotinylated IgG1 isotype control (10 mg/ml; BD), APC-conjugat-
ed anti-CD19 (2 mg/ml; clone 1D3; BD), APC-conjugated anti-
Ly-6G/C (4 mg/ml; clone RB6-8C5; eBiosience, Hatfield, UK),
APC-conjugated isotype control (4 mg/ml; eBiosience) or
MOMA1 (hybridoma supernatant, kindly provided by Dr. P.
Leenen). Secondary conjugates included biotinylated anti-rat
IgG2a (5 mg/ml; clone MARG2a-1; Serotec) and APC-conjugated
streptavidin (2 mg/ml; BD). pDC staining was performed using
Alexa Fluor 488-conjugated anti-CD11b, PE/Cy7-conjugated
anti-CD11c (Biolegend, San Diego, CA), PerCP-eFluor710-
conjugated anti-PDCA1 (eBioscience) and PE-conjugated anti-
B220 (BD). Cells were measured on a Facs Calibur or Facs Canto
II HTS and data was analysed using FlowJo software (version
8.8.6).
Immunofluorescence
Frozen sections (6 mm) were fixed for 10 min with acetone, air-
dried and washed with PBS/0.05% Tween. Aspecific binding was
blocked with 10% normal goat serum and primary antibodies in
PBS 1% BSA were allowed to bind for 1 h at room temperature
(20uC). Primary antibodies included MOMA-1 and ER-TR9 (anti-
CD209b) (both hybridoma supernatants, kindly provided by Dr. P.
Leenen). Sections were subsequently incubated with 5 mg/ml
Tetramethyl Rhodamine Isothiocyanate (TRITC)-labelled goat
anti-rat IgM or IgG (Southern Biotech Associates) and stained
with 6.67 mg/ml Alexa 647-labelled anti-B220 (clone RA3-6B2;
Biolegend). To prevent binding to anti-rat IgG-TRITC, sections
were blocked with 1% rat serum prior to incubating with anti-
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B220. Sections were mounted with Citifluor anti-fadent solution
(Citifluor Ltd., Leicester, UK).
Quantification of fluorescently labelled C. jejuni in spleen
sections
Six digital images (three per section) of splenic follicles were
taken from each animal using an Apotome Zeiss microscope.
Digital images were quantified using Fiji software. The total
CFSE-positive area (above threshold level) of all images was
calculated. In addition, the percentage of area containing CFSE
was determined within the sialoadhesin or CD209b-positive area.
Sections of PBS-injected animals and sections incubated with
secondary antibodies only were used to determine threshold levels.
Real-time quantitative PCR
Three to six 30-mm sections were cut from snap-frozen spleens
and kept on dry ice until further processing. Tissue was
homogenised in 500 ml RNA-Bee solution (Tel-Test, Friendswood,
TX, USA), 100 ml chloroform was added and samples were
thoroughly mixed. Following centrifugation, the aqueous phase
was collected and RNA was further purified using the GenElute
mammalian total RNA isolation kit (Sigma-Aldrich). Using 1 mg of
total RNA template, cDNA was prepared using SuperScript II
reverse transcriptase (Invitrogen) and oligo(dT) and random
hexamer primers. Cytokine and GAPDH RNA levels were
measured by real-time quantitative PCR analysis using the ABI
PRISM 7700 sequence detection system (Applied Biosystems).
PCR primers were spanning at least one intron/exon boundary.
Sequences for the primers and reference numbers for probes
(Universal Probe Library; Roche Applied Science) are listed in
Table S1. RNA levels were calculated relative to amounts found in
a standard sample, and cytokine levels were corrected for GAPDH
RNA levels to normalize for RNA input.
Serum cytokine ELISA
IFN-a and IFN-b levels were measured by ELISA (PBL) in
serum samples of mice sacrificed 3 h or 16 h after GB2 injection.
Assays were performed according to the manufacturer’s guide-
lines.
Statistical analysis
GraphPad Prism was used for all statistical analyses; t-test, t-test
with Welch’s corrections or Mann Whitney U as appropriate.
Data are represented as mean6 SD or SEM as indicated. P#0.05
was considered statistically significant and all tests were two sided.
Supporting Information
Figure S1 CFSE-labelling of wildtype and Cst-II knock-
out GB2 and GB11 results in comparable fluorescence
intensities. GB2 or GB11 wt and Cst-II mutant bacteria were
either left untreated (filled histograms) or were incubated with
1 mM CFSE for 30 min at 37uC, resulting in equal MFI.
(TIF)
Figure S2 Incubation of C. jejuni with BM-MW leads to
uptake into an intracellular location. BM-MW were
incubated with CFSE-labelled wt GB11 (green) at 37uC or 4uC
(with NaN3). A cytospin was made after 60 minutes and
internalisation of C. jejuni was visualised using fluorescence
microscopy, following mounting with DAPI containing media.
Shown is a z-stack of GB11 wt C. jejuni (GB11 ko gave similar
results). Inset in (C) shows clearly identifiable bacteria not present
in the top (A) or bottom (D) image, confirming phagocytosis.
(TIF)
Figure S3 Sialoadhesin is expressed on BM-MW and is
upregulated upon C. jejuni LOS stimulation. Cells were
stimulated overnight with GB11 wt or Cst-II mutant LOS and
sialoadhesin expression was examined by flow cytometry.
Sialoadhesin was expressed on unstimulated BM-MW (A; dotted
line) and was upregulated after stimulation with GB11 LOS (B,
and solid line in A). Filled histograms represent background
fluorescence when incubated with the secondary antibody alone.
BM-DC only express low levels of sialoadhesin and do not
upregulate sialoadhesin in response to GB11 LOS (C).
(TIF)
Figure S4 Type I interferon expression in response to C.
jejuni is pDC-independent.Mice were pretreated with 250 mg
120G8 antibody or an isotype control antibody, 24 h and 48 h
before injection with 108 GB2 wt bacteria. The majority of the
pDC were depleted as indicated by a strong reduction in the
percentage of PDCA1+ B220+ cells within the CD11b2 CD11c+
gate (A). Cytokine expression was determined in the spleen by
qPCR and revealed no significant differences between 120G8 and
control antibody treated mice (B).
(TIF)
Table S1 Primer sequences and probe numbers used
for real-time quantitative PCR.
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